The Intravitreal injectables market will be showcasing stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2023 to 2030. According to the statistics provided by World Health Organization (WHO) approximately 1.3 billion people throughout the globe are suffering with some form of blindness caused majorly due to macular degeneration, diabetic retinopathy, ocular vein occlusions, endophthalmitis and retinitis. Intravitreal injections are being preferred over other treatment options for treating disease associated visual impairment.
"Rising prevalence of diabetes and increasing geriatric population drive macular degeneration market growth"
As per the research citing of the Lancet journal the global prevalence rate of any age related macular degeneration is 8.69% with a higher prevalence rate in the Caucasian population followed by mongoloids. The primary factors that increase the risk factor for occurrence of macular degeneration are increasing geriatric population, smoking, obesity, genetic, diabetes etc. Diabetic retinopathy is a secondary disease manifestation occurring in elderly people having previous history of diabetes. Endophthalmitis is growing at faster rate owing to rise in air and water pollution and eye trauma.
"Excellent biocompatibility and impressive pharmacodynamic properties drive the anti-VEGF drugs market"
Anti-VEGF is dominating the drug class segment for Intravitreal injections market. Since its commercialization in 2006 drugs such as bevacizumab (Avastin), ranibizumab (Lucentis) etc. are considered as the first line drug therapy in patients suffering with neovascular age related macular degeneration and ocular vein occlusion. Its inherent features such as excellent biocompatibility and impressive pharmacodynamic properties has led to its increased popularity among ophthalmologist worldwide. Corticosteroids are used as an adjuvant drug therapy in alleviating inflammation caused due to eye infections. Antifungal drugs and antibiotics together are prescribed in eye infections such as endophthalmitis and retinitis.
"Rising prevalence of eye disorders and affordable reimbursement scenario drive the Intravitreal injectables market growth"
In the present situation North America is accountable for 37% market share in the regional segment for Intravitreal injectables market. As per the statistics provided by the Center for Disease Control and Prevention (CDC), approximately 3.3 million Americans aged 40 years and older are blind or suffering with low vision. Rising prevalence of eye disorders and affordable reimbursement scenario drive the market growth in North America. Europe represents 26% share on account of the presence of thriving healthcare infrastructure and domicile of key players such as Novartis AG, Allergan, Inc., Alimera Sciences, F.Hoffman-La Roche Ltd. etc. propel the market growth in Europe. Asia Pacific is holding 20% market share and is keen to capture the regional market in the near future on account of supportive regulatory environment provided by healthcare agencies and developing ophthalmic research centers providing optimum eye care.
Pharmaceutical giants competing to maintain stronghold in intravitreal injectables market are Allergan, Inc., Genetech, Inc., Alimera Sciences, Bristol-Myers Squibb Company, Eyetech, Inc., F.Hoffman-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., ThromboGenics, Inc. and Valeant Pharmaceuticals International, Inc.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Intravitreal Injectables market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2022-2032 |
Base Year | 2023 |
Forecast Period | 2024-2032 |
Historical Year | 2022 |
Unit | USD Million |
Segmentation | |
Indication
| |
Drug Class
| |
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report